July 21, 2026

Optiscan Imaging Advances Head and Neck Cancer Study Ahead of Schedule

Optiscan Imaging pushes Stage 2 of head and neck cancer live-imaging study ahead of schedule, accelerating clinical validation and potential FDA submissions. Optiscan Imaging (ASX: OIL) has begun Stage 2 of its first-in-human head and neck cancer imaging study at St...

recent articles

August 30, 2017

Under Repair

News and content will be delayed while we deal with medical issues here at tissuepathology.com. Guest authors and editors are needed if you would like to contact us as the news does not stop but additional capacity and resources are...

During the event, we will be showcasing our entire digital pathology portfolio. Here we are particularly proud to share our work in advancing PD-L1 testing based on the patented VirtualTripleStaining™ and its utility in automated assessment...

OR

platinum partners

gold partners

Silver Partners

Media Partners